Previous 10 | Next 10 |
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditio...
Sonoma Pharmaceuticals press release (NASDAQ:SNOA): FQ3 GAAP EPS of -$0.31. Revenue of $2.9M (-41.3% Y/Y). For further details see: Sonoma Pharmaceuticals GAAP EPS of -$0.31, revenue of $2.9M
Gross Profit Percentage for the Quarter ended December 31, 2021 Increased 1% versus Prior Year and 8% versus Prior Quarter Net loss per Share of $(0.31) for the Third Quarter Compared to a Net Loss per Share of $(0.32) for the Prior Year $8.5 Million of Cash and Stre...
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermat...
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it wi...
Sonoma Pharmaceuticals (NASDAQ:SNOA): Q2 GAAP EPS of -$0.04. Revenue of $3.74M (-35.2% Y/Y) Press Release For further details see: Sonoma Pharmaceuticals reports Q2 results
Revenues hold steady from prior quarter ended June 30, 2021 Net loss of $100,000, or $(0.04) per share for the second quarter compared to a net loss of $1.1 million or $(0.52) per share for the prior quarter ended June 30, 2021 Break-even EBITDAS for the quarter vers...
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its ...
Gainers: Jasper Therapeutics (NASDAQ:JSPR) +22%, 23andMe (NASDAQ:ME) +21%, DBV Technologies (NASDAQ:DBVT) +10%, ABVC BioPharma (NASDAQ:ABVC) +10%, Sonoma Pharmaceuticals (NASDAQ:SNOA) +8% Losers: Grove (NASDAQ:GRVI) -12%, Myomo (NYSE:MYO) -11%...
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its ...
News, Short Squeeze, Breakout and More Instantly...
Sonoma Pharmaceuticals Inc. Company Name:
SNOA Stock Symbol:
NASDAQ Market:
Sonoma Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and ...